Healthcare-Associated Infection (HAI) and the Role of Diagnostic Testing 1 Date, time, presenter etc. goes here For external use © 2014 Alere. All rights reserved. All trademarks referenced are trademarks of their respective owners /14

Healthcare-Associated Infections 2  An infection is ‘healthcare-associated’: - If developed in a patient hospitalized for at least 48 hours and infection not incubating at the time of admission (patient was not already infected) - If present on admission, was acquired during a previous admission or outpatient medical/surgical procedure - Also called nosocomial infections or hospital acquired infections

Impact of HAIs 3  HAIs erode a hospital’s bottom line by leading to increased length of stay with minimal to no reimbursement - ~1.7 million Americans (5% of all admissions) with HAI annually - Resulting in 99,000 deaths annually - $20-33 billion in extra costs Source: Amerinet HAI Prevention Tool Kit Presentation Public Health Reports. 2007; 122:

Impact of HAIs 4  Increased liability and risk for HAIs are creating the ‘perfect storm’ with changes in the regulatory environment, reimbursement practices and legal standards - 24% of hospital professional liability costs are associated with HAIs Source: Amerinet HAI Prevention Tool Kit Presentation - 10th Annual Hospital Professional Liability and Physician Liability Benchmark Analysis, 2009.

The Six Most Common HAIs 5  Central line-associated bloodstream infection (CLABSI)  Catheter-associated urinary tract infection (CAUTI)  Ventilator-associated pneumonia (VAP)  Surgical site infection (SSI)  C. difficile infection  MRSA infection Source: Amerinet HAI Prevention Tool Kit Presentation - 10th Annual Hospital Professional Liability and Physician Liability Benchmark Analysis, 2009.

Role of Microbiology in HAI Prevention 6 Critical to:  Outbreak management  Performing additional tests for epidemiologic analysis  Infection surveillance  Knowledge of new microbes or unusual resistance  Creating antibiograms  Education of healthcare staff

Alere HAI Positioning 7  Minimize the spread and enable focused treatment of healthcare-associated infections by identifying the cause sooner.  For healthcare institutions that need to mitigate risk associated with HAIs, Alere provides a portfolio that improves patient outcomes and reduces costs. Unlike complex methods, Alere offers versatile solutions to aid in the effective management of HAI.

The Alere Solution 8  Central line-associated BSI - S. aureus: Alere BinaxNOW ® S. aureus - MRSA: Alere ™ PBP2a Culture Colony Test  Ventilator-associated pneumonia - S. pneumoniae: Alere BinaxNOW ® S. pneumoniae - MRSA: Alere ™ PBP2a  Surgical site infection - MRSA: Alere ™ PBP2a  Transmission and antibiotic overuse - C. difficile: C. DIFF QUIK CHEK COMPLETE ® - MRSA: Alere ™ PBP2a  Hospital water contaminated w/Legionella - Alere BinaxNOW ® Legionella

Alere HAI Product Portfolio 9  Focused treatment  Identifying the cause sooner  Mitigates risk  Improves patient outcomes  Effective management of HAI © 2014 Alere. All rights reserved. The Alere Logo, Alere and BinaxNOW are trademarks of the Alere group of companies. C. DIFF QUIK CHEK COMPLETE is a trademark of TechLab, Inc. under license. All other trademarks referenced are trademarks of their respective owners /14